LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Urine Testing Differentiates Glomerular from Tubulointerstitial Diseases on Kidney Biopsy

By LabMedica International staff writers
Posted on 22 Apr 2022
Print article
Image: Randox Daytona RX chemical analyzer (Photo courtesy of Gemini BV)
Image: Randox Daytona RX chemical analyzer (Photo courtesy of Gemini BV)

Histological examination of kidney biopsy tissue can help differentiate between glomerular and tubulointerstitial diseases, as well as differentiate between their underlying etiologies and subtypes.

Several clinical urine tests are available to differentiate between glomerular and tubulointerstitial diseases. Clinically available tests include urinalysis, urine sediment microscopy, and urine albumin, which can indicate glomerular damage via features such as urinary presence of isomorphic or dysmorphic red blood cells (RBCs) and casts, or presence of proteinuria or albuminuria.

Clinical Scientists at the Yale School of Medicine (New Haven, CT, USA) and their colleagues enrolled patients scheduled to undergo a clinically indicated kidney biopsy at two Yale-affiliated hospitals from January 2015 to June 2018. Urine samples were collected during the outpatient biopsy procedure visit or during inpatient hospitalization. The team performed urine dipstick analysis using Clinitek Status analyzer (Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA) which reported specific gravity, pH, protein, ketone, blood, and leukocyte levels on an ordinal scale.

The team also performed urine sediment microscopy (Laxco LMC4BF, Mill Creek, WA, USA) and took representative pictures at 10× and 40× magnification, which were analyzed and reported by a trained nephrologist on an ordinal scale including RBCs, RBC casts, dysmorphic RBCs, WBCs, WBC casts, renal tubular epithelial (RTE) cells, RTE casts, and granular casts. The investigators measured urine albumin and creatinine measurements using Randox RX Daytona machine (Crumlin, UK) and the other urine biomarkers using manufacturer-validated panels using the Mesoscale Discovery platform (Rockville, MD, USA).

The scientists reported that of the final 359 participants, 121 (34%) had a histological diagnosis of glomerular disease, 89 (25%) had tubulointerstitial disease, and 149 (42%) had mixed glomerular and tubulointerstitial disease. Compared to patients with tubulointerstitial diseases, those with glomerular diseases had more dipstick hematuria (3+ versus 1+) and urine albumin (1.25 versus 0.09 mg/mg). Patients with glomerular diseases had higher levels of tubular health biomarkers (Uromodulin, 1.22 versus 0.92). In a multivariable model, higher urine albumin, dipstick blood, and urine uromodulin were independently associated with higher odds of glomerular diseases (test set AUC, 0.81).

The authors conclude that urine tests, including urine albumin, dipstick blood, and urine uromodulin, was associated with the histological diagnosis of glomerular disease. These findings can help clinicians differentiate between glomerular and tubulointerstitial diseases and guide clinical decisions regarding a kidney biopsy. The study was published on April 11, 2022 in the journal Practical Laboratory Medicine.

Related Links:
Yale School of Medicine 
Siemens Healthcare Diagnostics 
Laxco 
Randox 
Mesoscale Discovery 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more